Praxis Precision Medicines’ stock surges after positive results from a clinical trial of its epilepsy drug vormatrigine, which showed a 56.3% median reduction in seizure frequency among patients.

Praxis Precision Medicines, Inc. is a clinical-stage genetic neuroscience company focused on developing therapies for complex brain disorders, with a publicly traded stock reflecting the dynamic biotech sector.